Lonza Issues License to Antharis Therapeutics for ADCs
Lonza and Antharis Therapeutics announced an exclusive, target-specific licensing agreement to develop novel dual-payload ADCs targeting gastrointestinal (GI) cancers.
licensing agreement
Catalent and Elpida Therapeutics Join Forces for Gene Therapy Scale-Up
Catalent partners with non-profit Elpida Therapeutics to support late-phase AAV manufacturing for a rare neurological gene therapy, securing exclusive rights across Elpida's broader AAV pipeline.
Bristol Myers Squibb Bolsters Oncology Pipeline with Lonza Licensing Agreement
Bristol Myers Squibb licenses Lonza's SYNtecan linker-payload platform to advance an undisclosed ADC target, with Lonza eligible for upfront payments, milestones and royalties on resulting products.
Hongene to Supply exNA Oligonucleotide Technology Under New Licensing Deal
CDMO Hongene Biotech has entered a non-exclusive licensing agreement with the UMass Chan Medical School to produce and supply extended nucleic acid (exNA) monomers and exNA-modified oligonucleotides for research use.
Merck & Co. Licenses Investigational Cancer Drug from LaNova
US drugmaker Merck & Co. (MSD) has entered into a global license agreement to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from Chinese biotechnology company LaNova Medicines.
